On April 24, 2021 CiMaas reported that it is successful in expanding Natural Killer cells obtained from a small population in peripheral blood into very high numbers in just 2 weeks (Press release, CiMaas, APR 24, 2021, View Source [SID1234578431]). This is directly applicable for clinical application in anti-cancer therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CiMaas is actively working on multiple myeloma and breast cancer, but realises the NK cells can be used for many indications outside its’ own expertise where people are also desperately awaiting new therapies.

As CiMaas believes in collaboration, CiMaas would like to provide these cells to research groups that are interested in studying them in their in vitro cancer research and in vivo tumour models. CiMaas is also open for clinical partnerships to embark on other cancer types using NK cells produced under GMP compliancy.